Unifire to Focus on Distribution to Government Agencies and Humanitarian Efforts
VANCOUVER, BRITISH COLUMBIA, CANADA – MARCH 22, 2022 – Mission Ready Solutions Inc (“Mission Ready” or the “Company“) (TSX-V: MRS) (OTCQX: MSNVF) (FSE: 2R4), a provider of comprehensive government contracting solutions, is pleased to announce that, through its wholly-owned subsidiary, Unifire, Inc. (“Unifire“), the Company has entered into a Master Distribution and Marketing Agreement (the “Agreement“) with NuGen M.D. (TSX-V: NGMD) (“NuGen“), an emerging specialty medical device company focused on developing and commercializing novel drug delivery technologies.
As part of the Agreement, Unifire has been granted exclusive rights to sell NuGen’s needle-free injection device InsuJet™ into various US Government agencies and non-exclusive rights to sell into Government agencies in Israel and Australia. Unifire will act as NuGen’s Master Distributor in the United States with an immediate focus on opportunities within the Department of Defense (DoD), Biomedical Advanced Research and Development Authority (BARDA), Defense Advanced Research Projects Agency (DARPA), Veterans Affairs (VA), Department of Homeland Security (DHS) and Health and Human Services (HHS).
NuGen InsuJet™ needleless injection system is a revolutionary needle-free way to inject medication or vaccines and:
- Provides faster absorption of medicine than hypodermic needles
- Reduces fear and anxiety associated with hypodermic needles
- Eliminates needlestick injuries
- Reduces the risk of cross-contamination and infections
- Reduces cost burdens on the health care system
- Reduces cost for patients
- Reduces biohazard waste
“We are thrilled to have Unifire join our worldwide network of distributors with their deep understanding of the government contracting space, proven relationships, and track record of execution,” stated Michael Wright, CEO of NuGen. “Unifire will support NuGen in carrying out its expansion strategy in the US market by focusing on gaining acceptance for InsuJet™ as a safe, reliable and cost-effective replacement solution for current medication injection standard within Unifire’s well-established clientele of government agencies.”
Unifire will collaborate with NuGen to seek regulatory approval, garner political support, introduce non-dilutive government funding, while advising on the necessary manufacturing and supply chain requirements to be eligible to submit to government RFPs.
“A device with the demonstrated ability to safely, rapidly and effectively deliver critical medication has the potential to create a paradigm shift in the current standard of care in place within government agencies,” said Douglas Bryce, Advisory Committee member for Mission Ready and subject matter expert on development, acquisition, distribution, and deployment of Chemical, Biological, Radiological, and Nuclear (CBRN) defense devices and medical diagnostic systems, drugs and vaccines. “I strongly believe there are significant opportunities to deploy new and disruptive solutions within the Department of Defense, government-operated medical facilities, and their adoption into Tactical Combat Casualty Care.”
Jointly, the Companies will focus on opportunities within:
- Immediate Humanitarian Efforts to Provide Safe Access to Insulin treatments
- Global Vaccination Efforts
- Biomedical Advanced Research and Development Authority (BARDA)
- Defense Advanced Research Projects Agency (DARPA)
- Veterans Affairs (VA) for acceptance to support healthcare requirements
- DoD or government agencies with medical facilities
- Inclusion in Tactical Combat Casualty Care (TCCC)
Dan Raczykowski, Chief Operating Officer of Unifire, added, “Unifire prides itself in delivering best-in-class technologies that can provide solutions to critical needs. NuGen’s needle-free device, with its regulatory approval in more than 40 countries, could open new opportunities within our network, particularly in these times of need for humanitarian relief where access to life-saving medication represents a logistical challenge for certain populations. We are excited to join NuGen’s global distributor list while supporting their team on their path towards US regulatory approval.”
About the InsuJet™
The InsuJet™ is a revolutionary needle-free drug delivery device used to self-administer medication in a safe, fear-free, and virtually pain-free manner and is now approved for use in over 40 countries globally.
About NuGen Medical Devices
NuGen Medical Devices’ principal business is the development and commercialization of innovative needle-free injection devices and systems for subcutaneous medication administration.
It is developing products using needle-free drug delivery technology in several important fields including, but not limited to, anaphylaxis, diabetes, severe migraine, erectile dysfunction, chronic anemia, neutropenia, autoimmune rheumatoid arthritis, growth and fertility hormone, psoriasis as well as DNA and conventional/pediatric vaccines.
About Mission Ready Solutions Inc.
Mission Ready Solutions provides comprehensive government contracting solutions with extensive experience in delivering quality, reliable, mission-critical products and services for law enforcement, firefighters, first responders, military, and other governmental agencies.
Through its privileged access to a host of federal contracting vehicles, including Multiple Award Schedule (“MAS“) contracts awarded and administered by the United States General Services Administration, Mission Ready’s wholly-owned subsidiary, Unifire, Inc., leverages its robust vendor network, time-proven industry relationships, proprietary technology infrastructure, and industry-leading manufacturing and distribution capabilities to efficiently source and deliver more than 1.5 million products.
For further information on Mission Ready Solutions Inc., please visit MRSCorp.com.
You can also subscribe to our mailing list at eepurl.com/hznhX9 to receive our press releases and latest news directly by email.
Mission Ready Solutions Inc.
(Signed “Buck L. Marshall”)
Buck L. Marshall
President, CEO and Director
T: +1 877.479.7778
Investor Relations Contact:
T: +1 877.479.7778 (Ext.5)
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “forecast”, “project”, “budget”, “schedule”, “may”, “will”, “could”, “might”, “should” or variations of such words or similar words or expressions. Forward-looking information is based on reasonable assumptions that have been made by Mission Ready Solutions Inc. as at the date of such information and is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Mission Ready Solutions Inc. to be materially different from those expressed or implied by such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. Mission Ready Solutions Inc. does not undertake to update any forward-looking information that is included herein, except in accordance with applicable securities laws.